Stockreport

BioTime Initiates Dosing in Phase I/IIa Clinical Study of OpRegen for Treatment of Dry-AMD Utilizing Orbit Subretinal Delivery System

BlackRock Technology and Private Equity Term Trust Common Shares of Beneficial Interest  (BTX) 
NASDAQ:AMEX Investor Relations: biotimeinc.com/pexservice/investors
PDF ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing cellular therapies for unmet medical [Read more]